Search - tctmd.com

Displaying 1 - 20 of 31

Sort: Relevancy | Date

New ESC Guidelines Merge PAD, Aortic Diseases Into Single Document

News Conference News ESC 2024

New ESC Guidelines Merge PAD, Aortic Diseases Into Single Document

September 10, 2024

FDA Approves DETOUR for Percutaneous Bypass in Long, Complex SFA

News Conference News LINC 2023

FDA Approves DETOUR for Percutaneous Bypass in Long, Complex SFA

June 08, 2023

EMINENT: Better Patency With DES Over BMS for Fem-Pop Lesions

News Conference News VIVA 2021

EMINENT: Better Patency With DES Over BMS for Fem-Pop Lesions

October 12, 2021

Common-Femoral Lesions: LINC 2020 Experts Hash Out the Best PAD Treatment

News Conference News LINC 2020

Common-Femoral Lesions: LINC 2020 Experts Hash Out the Best PAD Treatment

January 31, 2020

News Conference News ISET 2020

FDA’s First Take on New Paclitaxel Concerns in CLI

January 24, 2020

Calcium Conundrum: New Scores, Research Aim to Boost Outcomes in PAD Interventions

News Conference News VIVA 2019

Calcium Conundrum: New Scores, Research Aim to Boost Outcomes in PAD Interventions

November 13, 2019

LEVANT: Patient-Level Data Show No Increase in 5-Year Death for Paclitaxel DCBs in PAD

News Conference News TCT 2019

LEVANT: Patient-Level Data Show No Increase in 5-Year Death for Paclitaxel DCBs in PAD

September 28, 2019

EffPac: Novel Paclitaxel DCB for PAD Demonstrates Efficacy With No Mortality Signal

News Conference News EuroPCR 2019

EFFPAC: Novel Paclitaxel DCB for PAD Demonstrates Efficacy With No Mortality Signal

May 23, 2019

Paclitaxel DCBs and CHIP: SCAI Kicks Off With Two Hot-Potato Topics

News Conference News SCAI 2019

Paclitaxel DCBs and CHIP: SCAI Kicks Off With Two Hot-Potato Topics

Yael L. Maxwell

May 21, 2019

Acknowledgment of Safety Signal for Paclitaxel Devices in PAD May Mark Sea Change in Controversy

News Conference News CRT 2019

Acknowledgment of Safety Signal for Paclitaxel Devices in PAD May Mark Sea Change in Controversy

March 06, 2019

PVI in Symptomatic Lower-Extremity PAD Offers Multiple Benefits, Even 2.5 Years Later

News Conference News ISET 2019

PVI in Symptomatic Lower-Extremity PAD Offers Multiple Benefits, Even 2.5 Years Later

February 07, 2019

Chelation for CLI in Diabetic Patients Shows Potential in Small Series

News Conference News ISET 2019

Chelation for CLI in Diabetic Patients Shows Potential in Small Series

January 29, 2019

PAD in the Spotlight: Awareness, Treatment Remain Low Despite Many Years of Research

News Conference News ISET 2019

PAD in the Spotlight: Awareness, Treatment Remain Low Despite Many Years of Research

January 28, 2019

Eluvia Gains FDA Approval Just Days After IMPERIAL Results Released

News Conference News TCT 2018

Eluvia Gains FDA Approval Just Days After IMPERIAL Results Released

September 24, 2018

IMPERIAL: Eluvia Tops Zilver PTX in Battle of DES in Femoropopliteal Disease

News Conference News TCT 2018

IMPERIAL: Eluvia Tops Zilver PTX in Battle of DES in Femoropopliteal Disease

September 22, 2018

COMPASS Approach Helps With Leg Complications in Patients With PAD

News Conference News ACC 2018

COMPASS Approach Helps With Leg Complications in Patients With PAD

March 12, 2018

Noninvasive Testing of CLI: Many Ways to Draw Up a ‘Roadmap’

News Conference News ISET 2018

Noninvasive Testing of CLI: Many Ways to Draw Up a ‘Roadmap’

February 05, 2018

Low-Dose Paclitaxel DCB Shows Long-term Durability in Treating PAD

News Conference News VIVA 2017

Low-Dose Paclitaxel DCB Shows Long-term Durability in Treating PAD

September 18, 2017

Bioresorbable Scaffolds for PAD: Does the Strategy Have Legs?

News Conference News ISET 2017

Bioresorbable Scaffolds for PAD: Does the Strategy Have Legs?

February 17, 2017

Targeted Delivery of Dexamethasone Combats Restenosis in Femoropopliteal Lesions: DANCE Trial

News Conference News ISET 2017

Targeted Delivery of Dexamethasone Combats Restenosis in Femoropopliteal Lesions: DANCE Trial

February 15, 2017

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.